Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An inherited metabolic disease that is has its basis in the disruption of cellular copper ion homeostasis.
No HPO annotations are available for this condition.
Age of onset: adolescence, at birth.
The clinical spectrum of ATP7A-related copper transport disorders ranges from classic Menkes disease at the severe end, to occipital horn syndrome (OHS), to isolated distal motor neuropathy (DMN) . Classic Menkes disease is characterized by neurodegeneration and failure to thrive commencing at age two to three months. The age at diagnosis is usually between four to eight months. In contrast, OHS presents in early-to-middle childhood and is characterized predominantly by connective tissue abnormalities. ATP7A-related DMN is an adult-onset disorder resembling Charcot-Marie-Tooth hereditary neuropathy; it shares none of the clinical abnormalities characteristic of classic Menkes disease or OHS.
An ATP7A-related copper transport disorder (Menkes disease, occipital horn syndrome, or ATP7A-related distal motor neuropathy) should be suspected in individuals with the following clinical and laboratory findings.
Classic Menkes disease is suspected in males who develop hypotonia, failure to thrive, and seizures between age six and twelve weeks. Shortly thereafter, hair changes become manifest: the scalp and (usually) eyebrow hair is short, sparse, coarse, twisted, and often lightly pigmented (white, silver, or gray). The hair is shorter and thinner on the sides and back of the head. The hair can be reminiscent of steel wool cleaning pads.
No approved treatments are currently available for disorder of copper metabolism. The disease remains an area of unmet medical need.
No formal clinical practice guidelines for ATP7A-related copper transport disorders have been published.
To establish the extent of disease and needs in a male diagnosed with an ATP7A-related copper transport disorder, the evaluations summarized in , , and (if not performed as part of the evaluation that led to the diagnosis) are recommended.
For infants being treated with CuHis (or temporarily with CuCl2), monitor serum copper and ceruloplasmin levels to avoid supranormal levels. Table 5a. Recommended Surveillance for a Male with Menkes Disease
System/Concern |
|---|
No clinical trials have been registered for disorder of copper metabolism.
60 publications have been identified in PubMed for disorder of copper metabolism. Research spans Case Report / Case Series (27%), Review / Meta-Analysis (20%), and Basic Science / Preclinical (15%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 16 | 27% |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 4:11 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Infants appear healthy until age two to three months, when loss of early devel...
Source: GeneReviews — "ATP7A-Related Copper Transport Disorders"
Source: GeneReviews — "ATP7A-Related Copper Transport Disorders"
Menkes disease. While classic Menkes disease often presents with a highly distinctive clinical and biochemical phenotype, a differential diagnosis may include other infantile-onset neurodevelopmental syndromes, including:
• Biotinidase deficiency
Organic acidurias
Aminoacidurias
Mitochondrial myopathies (See Mitochondrial Disorders Overview.)
Occipital horn syndrome. The differential diagnosis includes any conditions that involve skin and/or joint laxity, including:
FBLN5-related cutis laxa, inherited in an autosomal recessive or (less commonly) autosomal dominant manner and caused by pathogenic variants in FBLN5;
ELN-related cutis laxa, inherited in an autosomal dominant manner and caused by pathogenic variants in ELN;
EFEMP2-related cutis laxa.
Source: GeneReviews — "ATP7A-Related Copper Transport Disorders"
Biomarker and diagnostic research for disorder of copper metabolism has been reported in the published literature.
Table 3a.
Recommended Evaluations Following Initial Diagnosis in Individuals with Classic Menkes Disease Phenotype
System/Concern | Evaluation | Comment
| Neurologic eval | • Incl brain imaging (MRI/MRA) to assess degree of cerebral/cerebellar atrophy.
Consider EEG if seizures present.
Assess for signs/symptoms of autonomic dysfunction (dizziness, syncope, chronic diarrhea).
| Developmental assessment | • To incl gross motor, fine motor, personal-social, language development
Eval for early intervention/ special education /or PT, OT, speech therapy
Gastrointestinal/
| Gastroenterology/ nutrition/ feeding team eval | • To incl eval of aspiration risk nutritional status
Consider eval for gastrostomy tube placement in those w/dysphagia /or aspiration risk.
Evaluate for umbilical /or inguinal hernias.
Evaluate for gastric polyps.
| Pediatric nephrology/urology | Pelvic ultrasound
Pulmonary/
| Assess for recurrent pneumonias | Chest radiographs (PA lateral) if symptoms occur
Genetic
Source: GeneReviews — "ATP7A-Related Copper Transport Disorders"
CuHis received FDA FastTrack (2018) and Breakthrough (2020) designations from the US Food and Drug Administration and the European Medicines Agency Committee for Orphan Medicinal Products issued a positive opinion for Orphan Drug Designation in 2020. An expanded access clinical trial that provides CuHis for individuals with Menkes disease in the US (NCT04074512) is currently in progress. For updated preliminary results on subcutaneous CuHis treatment for Menkes disease, click here. Adeno-associated viral (AAV) gene therapy in combination with copper has also been investigated in Menkes disease mouse models, with promising results .
Source: GeneReviews — "ATP7A-Related Copper Transport Disorders"
View trials for disorder of copper metabolism
Evaluation |
|---|
Frequency |
|---|
Neurologic | Monitor those w/seizures as clinically indicated. | At each visit Assess for new manifestations such as seizures, changes in tone, movement disorders. |
Development | Monitor developmental progress educational needs. | At each visit Growth/ Nutrition |
Respiratory | Assess for recurrent pulmonary infections. | Family/ |
Community | Assess family need for social work support (e.g., home nursing, other local resources; coordination of care; need for palliative/respite care). | At each visit OT = occupational therapy; PT = physical therapy Table 5b. |
Recommended Surveillance for a Male with Occipital Horn Syndrome System/Concern | Evaluation | Frequency |
Autonomic dysfunction (dizziness, syncopal episodes) | Consider orthostatic blood pressures (supine standing). | At each visit Development |
Bladder diverticula | Pelvic ultrasound | Annually Table 5c. |
Source: GeneReviews — "ATP7A-Related Copper Transport Disorders"
12 |
20% |
Laboratory research | 9 | 15% |
Disease patterns and progression | 8 | 13% |
Testing and diagnosis research | 6 | 10% |
Clinical study results | 4 | 7% |
New treatment approaches | 4 | 7% |
Other research | 1 | 2% |
He L (2026). [PMID: 42063756](https://pubmed.ncbi.nlm.nih.gov/42063756/). *Front Med (Lausanne)*. [Case Report / Case Series]
Wang SH (2026). [PMID: 41763036](https://pubmed.ncbi.nlm.nih.gov/41763036/). *Stem cell research*. [Basic Science / Preclinical]
Ding D (2026). [PMID: 41423099](https://pubmed.ncbi.nlm.nih.gov/41423099/). *International journal of biological macromolecules*. [Basic Science / Preclinical]
Hasani E (2026). [PMID: 42126658](https://pubmed.ncbi.nlm.nih.gov/42126658/). *Mol Biol Rep*. [Case Report / Case Series]
Xu Z (2026). [PMID: 41935168](https://pubmed.ncbi.nlm.nih.gov/41935168/). *Sci Rep*. [Epidemiology / Natural History]
Alghamdi S (2026). [PMID: 42070021](https://pubmed.ncbi.nlm.nih.gov/42070021/). *BMC Gastroenterol*. [Case Report / Case Series]
Folhoffer A (2026). [PMID: 42196798](https://pubmed.ncbi.nlm.nih.gov/42196798/). *Diagnostics (Basel)*. [Diagnostic / Biomarker]
Wang Z (2026). [PMID: 41780554](https://pubmed.ncbi.nlm.nih.gov/41780554/). *Clinical and molecular hepatology*. [Gene Therapy / Novel Therapeutics]
Li Y (2026). [PMID: 42038238](https://pubmed.ncbi.nlm.nih.gov/42038238/). *Front Pediatr*. [Case Report / Case Series]
Fang W (2026). [PMID: 41568204](https://pubmed.ncbi.nlm.nih.gov/41568204/). *RSC advances*. [Gene Therapy / Novel Therapeutics]